For example, carotuximab, a humanized monoclonal antibody that can potentially inhibit CD105-mediated signaling, has shown limited clinical benefit as an anti-angiogenic agent in prostate cancer patients [45]. The gene discussed is ENG; the disease is prostate carcinoma.